David C Hodgson1, Cecilia Cotton1, Pavel Crystal1, Paul C Nathan1. 1. Affiliations of authors:Department of Radiation Oncology and Institute for Health Policy, Management and Evaluation , University of Toronto, Toronto, Canada (DCH), Department of Pediatrics (PCN), and Joint Department of Medical Imaging, Mount Sinai Hospital and University Health Network (PC); Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network , Toronto , Canada (DCH); Department of Statistics and Actuarial Science, University of Waterloo , Waterloo , Canada (CC); Division of Hematology/Oncology Hospital for Sick Children , Toronto , Canada (PCN).
Abstract
BACKGROUND: Female survivors treated with thoracic radiation therapy (RT) for childhood cancer experience increased risks of breast cancer (BC). There are currently no data quantifying the potential mortality gains of early BC screening among such survivors. METHODS: A mathematical model of BC development was used to evaluate the marginal benefit of early-initiated screening of female survivors of adolescent Hodgkin's lymphoma (HL) starting at age 25 years on BC mortality compared with screening initiated at age 40 years. Sensitivity analyses were performed to evaluate the robustness of the estimates over a plausible range of conditions. RESULTS: For survivors treated at age 15 years, the absolute risk of BC mortality by age 75 years was predicted to decrease from 16.65% with no early screening to 16.28% (annual mammography), 15.40% (annual MRI), 15.38% (same-day annual mammography and MRI), and 15.37% (alternating mammography and MRI every six months). Approximately 80 patients would need to be invited to MRI-based screening to prevent one BC death. In sensitivity analyses, the number needed to invite to MRI-based screening to prevent one BC death ranged from 71 to 333. Combinations of MRI plus mammography were predicted to produce 99.52 false positives per 1000 screenings done between age 25 to 39 years. CONCLUSIONS: These findings are the first to indicate that early MRI-based screening should reduce BC mortality among women treated with RT for adolescent HL. The magnitude of this benefit is superior to that described for other accepted screening indications although MRI can produce a substantial rate of false-positive results.
BACKGROUND: Female survivors treated with thoracic radiation therapy (RT) for childhood cancer experience increased risks of breast cancer (BC). There are currently no data quantifying the potential mortality gains of early BC screening among such survivors. METHODS: A mathematical model of BC development was used to evaluate the marginal benefit of early-initiated screening of female survivors of adolescent Hodgkin's lymphoma (HL) starting at age 25 years on BC mortality compared with screening initiated at age 40 years. Sensitivity analyses were performed to evaluate the robustness of the estimates over a plausible range of conditions. RESULTS: For survivors treated at age 15 years, the absolute risk of BC mortality by age 75 years was predicted to decrease from 16.65% with no early screening to 16.28% (annual mammography), 15.40% (annual MRI), 15.38% (same-day annual mammography and MRI), and 15.37% (alternating mammography and MRI every six months). Approximately 80 patients would need to be invited to MRI-based screening to prevent one BC death. In sensitivity analyses, the number needed to invite to MRI-based screening to prevent one BC death ranged from 71 to 333. Combinations of MRI plus mammography were predicted to produce 99.52 false positives per 1000 screenings done between age 25 to 39 years. CONCLUSIONS: These findings are the first to indicate that early MRI-based screening should reduce BC mortality among women treated with RT for adolescent HL. The magnitude of this benefit is superior to that described for other accepted screening indications although MRI can produce a substantial rate of false-positive results.
Authors: Jennifer M Yeh; Kathryn P Lowry; Clyde B Schechter; Lisa R Diller; Oguzhan Alagoz; Gregory T Armstrong; John M Hampton; Wendy Leisenring; Qi Liu; Jeanne S Mandelblatt; Diana L Miglioretti; Chaya S Moskowitz; Kevin C Oeffinger; Amy Trentham-Dietz; Natasha K Stout Journal: Ann Intern Med Date: 2020-07-07 Impact factor: 25.391
Authors: Matthew J Ehrhardt; Carrie R Howell; Karen Hale; Malek J Baassiri; Carol Rodriguez; Carmen L Wilson; Surekha S Joshi; Thomas C Lemond; Sheila Shope; Rebecca M Howell; Zhaoming Wang; Deokumar Srivastava; Daniel A Mulrooney; Jinghui Zhang; Leslie L Robison; Kirsten K Ness; Melissa M Hudson Journal: J Clin Oncol Date: 2019-05-10 Impact factor: 44.544
Authors: Anne Blaes; Rachel I Vogel; Rebekah H Nagler; Alicia Allen; Susan Mason; Deanna Teoh; Kristine Talley; Nancy C Raymond; Jean F Wyman Journal: J Womens Health (Larchmt) Date: 2019-08-21 Impact factor: 2.681
Authors: Kevin C Oeffinger; Jennifer S Ford; Chaya S Moskowitz; Joanne F Chou; Tara O Henderson; Melissa M Hudson; Lisa Diller; Aaron McDonald; James Ford; Nidha Z Mubdi; Dayton Rinehart; Christopher Vukadinovich; Todd M Gibson; Nassim Anderson; Elena B Elkin; Kathleen Garrett; Margaret Rebull; Wendy Leisenring; Leslie L Robison; Gregory T Armstrong Journal: J Clin Oncol Date: 2019-07-01 Impact factor: 44.544
Authors: Adam P Yan; Yan Chen; Tara O Henderson; Kevin C Oeffinger; Melissa M Hudson; Todd M Gibson; Joseph P Neglia; Wendy M Leisenring; Kirsten K Ness; Jennifer S Ford; Leslie L Robison; Gregory T Armstrong; Yutaka Yasui; Paul C Nathan Journal: J Clin Oncol Date: 2020-03-06 Impact factor: 44.544
Authors: Scott C Adams; Jennifer Herman; Iliana C Lega; Laura Mitchell; David Hodgson; Kim Edelstein; Lois B Travis; Catherine M Sabiston; Paaladinesh Thavendiranathan; Abha A Gupta Journal: JNCI Cancer Spectr Date: 2020-10-28